Form 4: OptimizeRx Director Ellen O'Connor Vos Receives Significant RSU Grant

OptimizeRx Corporation's Director, Ellen O'Connor Vos, was granted 9,868 restricted stock units (RSUs) on June 11, 2025, as part of her compensation.

Summary

• Ellen O'Connor Vos, a Director of OptimizeRx Corp (OPRX), acquired 9,868 shares of common stock through a grant of restricted stock units (RSUs).
• The transaction occurred on June 11, 2025, with a reported acquisition price of $0 per share, indicating a grant rather than a purchase.
• Following this transaction, Ms. Vos beneficially owns a total of 72,642 shares of OptimizeRx common stock.
• The granted restricted stock units are contingent rights to receive shares and will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The document reports a standard insider transaction (RSU grant) which is a positive for aligning director and shareholder interests, but it does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of restricted stock units to a director aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of non-cash compensation for board members, reflecting ongoing commitment and participation.

Future Outlook

The granted restricted stock units are scheduled to vest in full on the earlier of June 11, 2026 (first anniversary of grant) or the date of OptimizeRx's next annual meeting of shareholders, indicating a future inflow of shares to the director.

Industry Context

The grant of restricted stock units (RSUs) to a director is a common practice in the pharmaceutical technology and healthcare IT sectors, as well as across publicly traded companies, to compensate board members and align their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) as part of director compensation is a widely accepted practice across various industries, including healthcare technology, and is consistent with corporate governance best practices aimed at aligning director incentives with shareholder returns.
• While specific grant sizes vary based on company size, performance, and board structure, the mechanism of using RSUs with a vesting schedule is a standard compensation tool for non-employee directors, similar to practices observed at companies like Veeva Systems (VEEV) or IQVIA (IQV) for their board members.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making.
• Director (Ellen O'Connor Vos): Receives equity compensation, increasing her stake and financial incentive in the company's success.

Next Steps

• The restricted stock units will vest in full on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the Company's next annual meeting of shareholders, at which point the shares will be delivered to Ms. Vos.

Key Dates

Keywords

OptimizeRx, OPRX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Beneficial Ownership, Equity Compensation